Gilead Buys into Tizona's Anti-HLA-G Strategy
- PMID: 32816990
- DOI: 10.1158/2159-8290.CD-NB2020-077
Gilead Buys into Tizona's Anti-HLA-G Strategy
Abstract
Gilead announced plans in July to pay $300 million for a 49.9% stake in Tizona Therapeutics, with the option to buy the rest of the company for $1.25 billion. Whether Gilead follows through with the acquisition will hinge on how well Tizona's investigational HLA-G inhibitor, TTX-080, fares in early-stage clinical trials.
©2020 American Association for Cancer Research.
Publication types
LinkOut - more resources
Full Text Sources
Research Materials
